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Primary Care Trust (PCT) estimates of survival lack robustness as there are small numbers of deaths per year in each area, even when
incidence is high. We assess PCT-level spatial variation in prostate cancer survival using Bayesian spatial models of excess mortality.
We extracted data on men diagnosed with prostate cancer between 1990 and 1999 from the Northern and Yorkshire Cancer
Registry and Information Service database. Models were adjusted for age at diagnosis, period of diagnosis and deprivation. All
covariates had a significant association with excess mortality; men from more deprived areas, older age at diagnosis and diagnosed in
1990–1994 had higher excess mortality. The unadjusted relative excess risks (RER) of death by PCT ranged from 0.75 to 1.66. After
adjustment, areas of high and low excess mortality were smoothed towards the mean, and the RERs ranged from 0.74 to 1.49. Using
Bayesian smoothing techniques to model cancer survival by geographic area offers many advantages over traditional methods;
estimates in areas with small populations or low incidence rates are stabilised and shrunk towards local and global risk estimates
improving reliability and precision, complex models are easily handled and adjustment for covariates can be made.
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Five-year relative survival rates from prostate cancer in England
and Wales have increased from 43% for men diagnosed during
1986–1990 to 68% for men diagnosed in 1996–1999. The
deprivation gap in survival also increased over this time period
to a difference of 7% between men from the most affluent areas
compared with men from the most deprived areas (Coleman et al,
2004). This increase in survival reflects the increased use of
prostate-specific antigen (PSA) testing, which has led to the
diagnosis of many asymptomatic prostatic cancers that would
never have been diagnosed in life (Brewster et al, 2000; Evans and
Moller, 2003).
Survival from prostate cancer is known to vary among different
geographic regions. The EUROCARE study found that there was
considerable variation in survival between countries, with England
having one of the lowest survival rates (Post et al, 1998;
EUROCARE, 2003; Berrino et al, 2007). Significant geographical
variation in prostate cancer survival has also been observed in
Australia (Yu et al, 2004), the Nordic Countries (Dickman et al,
1997) and the United States (Farrow et al, 1996). Within the
Northern and Yorkshire regions the 5-year relative survival from
prostate cancer has been shown to vary by cancer network from 62
to 72% (NYCRIS, 2004).
Most regional analyses of survival estimate rates for each region
separately and compare them to assess the regions that are
statistically different from each other. This leads to problems with
multiple testing; if there are many areas some will be found to be
statistically significantly different through chance alone. In
addition, areas with sparse data will have large confidence intervals
and will produce unstable estimates of survival rates. Furthermore,
independently estimating the survival rates for each area makes no
use of data in the surrounding areas. The result is that the area-
specific estimates of survival rate have low power and validity, in
addition to poor precision.
Most of these problems can be overcome by statistical
smoothing techniques, which by borrowing and sharing data
across areas, produce more reliable estimates of risk. In particular,
estimates are stabilised and shrunk towards average values; thus
overcoming the problems of areas with small populations or low
incidence rates. Of the many methods available, Bayesian methods
are commonly used to generate smoothed estimates of risk in
cancer relative survival (Yu et al, 2004). Bayesian methods are
proving useful and applicable because of the ease with which prior
information is included in the analyses; moreover, complex and
realistic models are easily handled as opposed to traditional
methods. In using a Bayesian approach, we obtain posterior
Received 9 June 2008; revised 25 September 2008; accepted 1 October
2008; published online 4 November 2008
*Correspondence: L Fairley; E-mail: lesley.fairley@nycris.leedsth.nhs.uk
British Journal of Cancer (2008) 99, 1786–1793
& 2008 Cancer Research UK All rights reserved 0007– 0920/08 $32.00
www.bjcancer.com
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sdistributions of all the model parameters and their functions such
as relative contributions of the unstructured and structured spatial
effect variations.
There has been a trend in the last few years within epidemiology
to perform spatial variation of diseases risk at the smallest
geographical area such as electoral wards. However, in the case of
cancer survival where there is a need to calculate expected deaths
in follow-up intervals (usually yearly intervals), the observed
deaths are very sparse, which makes the assumptions on which
estimating methods are based invalid. (Rachet and Coleman, 2004)
Cancer survival estimates are not routinely produced at Primary
Care Trust (PCT) levels, as PCT level estimates of survival are
insufficiently robust. Rachet and Coleman (2004) found that
annual estimates of relative survival might not be reliable for PCTs
because of small numbers of deaths, even in cancers where the
incidence is high. That report was based on the PCTs prior to the
most recent reorganisation in October 2006; however, even the
newly configured PCTs, although much larger than the previous
ones, are still too small to be used as geographic units for
monitoring cancer survival. (Ellis et al, 2007) Using Bayesian
smoothing methods to estimate survival for each PCT will
overcome many of these problems by borrowing and sharing data
across areas overcoming the problems with areas with low
incidence or few deaths. We have used PCT (using pre October
2006 boundaries) as our level of analysis. Moreover PCTs are a
logical unit to use as they are the focus of most of the NHS cancer
policy and responsible for delivering care to patients and
commissioning services within that area. It is also important not
only to provide an estimate for each PCT, but also to see how these
estimates relate to other PCTs.
We set out to apply full Bayesian smoothing techniques using
hierarchical models to assess PCT-level spatial variation in
prostate cancer relative survival. By, taking into account both
local and global risk smoothing, these methods produce more
reliable, precise and robust estimators for PCT-specific variation in
prostate cancer relative survival. We also investigated if the spatial
variation in survival can be explained by socio-demographic risk
factors, age, deprivation and period of diagnosis.
MATERIALS AND METHODS
Data
The Northern and Yorkshire Cancer Registry and Information
Service (NYCRIS) is a population-based cancer registry covering a
total population of 6.7 million (at the 2001 Census). The analysis in
this paper is based on the Primary Care Trust boundaries that were
effective until October 2006. Within the NYCRIS region there were
44 PCTs during this time period. The average size of the PCT
populations in 2001 was just under 150000, this ranged from just
under 70000 in Eden Valley to about 307000 in Northumberland.
All prostate cancer (ICD10 C61) cases diagnosed in the NYCRIS
region between 1990 and 1999 were extracted from the registry
database (n¼22042). These cases were then followed up for death
until 31 December 2004. There were 492 cases that were Death
Certificate Only and no date of diagnosis was available for these
cases so they were excluded from the analysis. Cases aged over 100
at diagnosis and cases that were multiple primaries were also
excluded from the analysis (2097 cases). This left 19453 cases to be
included in the survival analysis but a further 45 cases had the date
of diagnosis the same as the date of death and therefore had zero
survival time and were also excluded from the analysis. The
resulting study population consisted of 19408 men diagnosed with
prostate cancer between 1990 and 1999 and followed up till the end
of 2004.
For each patient we also obtained their age at diagnosis, ward
and PCT of residence at diagnosis and year of diagnosis. Age was
grouped into four different categories – 15–59 years, 60–69 years,
70–79 years and 80þ years. Deprivation was measured at the
ward level and derived from the Index of Multiple Deprivation
2004 Income domain scores (Nobel et al, 2004); each patient was
assigned a deprivation quintile based on their ward of residence.
Year of diagnosis was split into two time periods 1990–1994 and
1995–1999.
Statistical methods
Relative survival Relative survival is the preferred method of
survival analysis for population-based cancer survival. The cause
of death is not reliably reported for all cancer patients and even
with access to medical records it is difficult to classify each
patient’s death into one of the two categories ‘entirely due to
cancer’ or ‘entirely unrelated to cancer’. Therefore, rather than
using cause-specific survival, relative survival is used when
calculating survival from cancer. Relative survival is the ratio of
the observed proportion surviving in a group of patients to the
expected proportion that would have survived in a comparable
group of people (with for example, the same distribution by age,
sex and the geographical area) from the general population. The
major advantage of this measure is that information on cause of
death is not required and it provides a measure of the excess death
rate experienced by patients diagnosed with cancer, irrespective of
whether the excess is directly or indirectly attributable to the
cancer (Ederer et al, 1961; Hakulinen and Tenkanen, 1987).
Modelling relative survival To model the relative survival so we
could include covariates in the analysis we fitted a Poisson model
for relative survival as described in Dickman et al (2004) and
Pohar and Stare, (2006) assuming an additive hazard model. The
hazards are assumed to be constant within pre-specified sub
intervals of follow-up time (that is, piecewise constant hazards). In
this study, we have used follow-up intervals of 1 year. A set of
indicator variables was constructed, one indicator variable for each
interval, and incorporated into the covariate vector. Our primary
interest is in the excess hazard component, which is assumed to be
an exponential function of the covariates, written as exp(zb) where
z is the vector of predictor variables with the associated vector of
coefficients in b, that is, the Cox model. Parameters representing
the effect in each follow-up time interval are estimated in the same
way as parameters representing the effect of, for example, age or
sex. In our models we have age at diagnosis (four categories)
deprivation quintile (five categories) and period of diagnosis (two
categories) as covariates.
We assume that patients are grouped into k strata based on a
combination of the relevant predictors, that is, one stratum for
each combination. Furthermore, assume that there are i intervals
of follow up. Following Dickman et al (2004) let the number of
deaths, dki, be distributed as a Poisson distribution, dkiBPois-
son(mki) where mki¼lkiyki and yki is person time at risk for the
observations in stratum k in the interval i. If we denote dki* as the
expected number of deaths in stratum k and interval i, then
lnðmki   d 
kiÞ¼lnðykiÞþzb ð1Þ
Note that dki* is the expected number of deaths (due to causes
other than the cancer of interest and estimated from general
population mortality rates). This is a generalised linear model with
outcome dki with a Poisson error structure and a link function
ln(mki dki*) with offset ln(yki). This is not a standard link function
so fitting the model requires software which allows user-defined
link functions, in our analysis we fitted it in WinBUGS
(Spiegelhalter et al, 2004). The exponentiated parameter estimates
have an interpretation as excess hazard ratios also known as
relative excess risk (RER).
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sWe used the Stata macro strs, written by Paul Dickman
(available from http://www.pauldickman.com) to calculate expec-
ted survival using the Ederer II method (Dickman et al, 2008),
using lifetables derived specifically for the Northern and Yorkshire
region. Each individual’s follow up time was censored at 5 years.
For each individual we estimated the expected number of deaths in
each follow up interval and also the person time at risk as well as
an indicator of whether or not they died in that interval. We then
aggregated these values for each PCT for each combination of
covariates in each follow up period (4 age groups 5 deprivation
groups 2 periods of diagnosis¼40 combinations of covariate
groups (5 follow up periods and 44 PCTs)).
Bayesian spatial models We used Bayesian spatial models to fit
both local and global smoothed estimates of relative excess risk
across the 44 PCTs (Besag et al, 1991). This was done by modifying
(1) to include PCT random effects
lnðmki   d 
kiÞ¼lnðykiÞþzb þ ul þ vl; l ¼ 1;K...;44
where u1 and v1 are the unstructured and structured random
effects, which are assigned a normal and a conditional auto-
regressive prior distribution. The former smoothes the relative
risks towards a global value, whereas the latter towards the mean
risk of the neighbouring areas, with variance inversely propor-
tional to number of neighbours (Besag et al, 1991). Unstructured
heterogeneity variance (s
2) and conditional spatial variance (y
2)
are each given g prior distributions with scale parameter 0.5 and
shape parameter 0.001.
Relative contributions of spatial and unstructured
heterogeneity in the convolution model
Unstructured heterogeneity variance (s
2) and spatial variance (y
2)
are not directly comparable, s
2 reflects marginal variability of the
unstructured random effects between areas whereas, y
2/n1 reflects
conditional variance of the spatial effect of area l conditional on
the values of the neighbouring spatial effects, where n1 is the
number of neighbours of area l. Therefore, we have to estimate the
marginal spatial variance empirically where,
y
2
marginal ¼
X
l
ðvl     vÞ
2=ðI   1Þ
From this we can then estimate the relative contributions of spatial
and unstructured heterogeneity. We define the spatial fraction
(Frac spatial) as
Fracspatial ¼ y
2
marginal=ðy
2
marginal þ s2Þ
If the spatial fraction is close to 1 then the spatial heterogeneity
dominates and if the spatial fraction is close to 0 then the
unstructured heterogeneity dominates. Spatially structured
variance measures the amount of local smoothing whereas
the unstructured variance measures global smoothing in the
PCT-relative risks. In the model where possible risk factors are not
included, these show the overall variation, otherwise they show
excess variation above that captured by the included risk factors.
We compared this spatial fraction after including different
variables in the model to see how much of the geographical
variation between PCTs can be explained by the risk factors.
We fitted four different models, one unadjusted (only including
the follow up interval) one adjusted for each covariate in turn and
one fully adjusted model, which included all covariates. We used
the Deviance Information Criterion (DIC) to asses the model fit
(Spiegelhalter et al, 2002) where the model with the smaller DIC is
better supported by the data. We used a ‘burn-in’ period of 40000
iterations and then ran a further 40000 iterations to obtain the
posterior estimates. We report the median and 95% credible
intervals for the posterior summaries. For comparison we also
fitted the models in Stata to obtain RERs for each PCT using a
classical Poisson model.
RESULTS
Table 1 shows the distribution of the demographic variables in the
study population, with the corresponding 5-year survival and
Figure 1 shows the Kaplan–Meier survival curves up to 5 years of
follow up by each of the demographic variables. Over 90% of the
men were aged 60 and over at diagnosis with 43% of them aged
70–79 years. There were more men from the more deprived areas
than the most affluent areas (15% of men were in the most affluent
deprivation quintile compared with 24% of men in the most
deprived quintile). Slightly more men were diagnosed in the later
time period (56%) than in the earlier time period (44%). The
overall Kaplan–Meier 5-year survival rate for men diagnosed with
prostate cancer in the NYCRIS region was 41% (95% CI 41–42).
Survival decreased as age at diagnosis increased; men aged 15–59
years at diagnosis had a 5-year survival rate of 62% whereas it was
only 19% for men aged 80 and over at diagnosis. There was a
difference of about 8 percentage points in the 5-year survival of
Table 1 Demographic characteristics of the study population and Kaplan–Meier 5-year survival rates
Variable N % 5-year Kaplan–Meier survival (%) 95% CI
All cases 19408 41.2 (40.5, 41.9)
Age group
15–59 years 1123 5.79 62.4 (59.5, 0.65.2)
60–69 years 4920 25.35 56.8 (55.4, 58.1)
70–79 years 8432 43.45 42.2 (41.1, 43.2)
80+ years 4933 25.42 19.3 (18.2, 20.4)
Deprivation quintile
1 (most affluent) 2809 14.47 45.5 (43.7, 47.3)
2 3612 18.61 45.1 (43.5, 46.7)
3 3662 18.87 41.1 (39.5, 42.7)
4 4638 23.90 39.3 (37.9, 40.7)
5 (most deprived) 4687 24.15 37.7 (36.3, 39.0)
Period of diagnosis
1990–1995 8556 44.08 35.0 (34.0, 36.0)
1996–2000 10852 55.92 46.1 (45.2, 47.1)
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smen from the most affluent areas compared with those from the
most deprived (46 and 38% respectively). The 5-year survival rate
of men diagnosed between 1990 and 1994 was significantly lower
than for men diagnosed between 1995 and 1999 (35 and 46%
respectively).
The graph in Figure 2 shows the 5-year relative survival rates by
PCT. The overall survival rate in the NYCRIS region was 56% (95%
CI 55.4–57.3), this ranged from 34% in West Cumbria PCT to 72%
in Eden Valley PCT. There were five PCTs that had a significantly
higher relative survival rate than the NYCRIS rate and five PCTs
that had a significantly lower relative survival rate.
Table 2 shows the results from the Bayesian Poisson models of
excess mortality for the unadjusted, univariate and fully adjusted
models. The last column also shows the results from the classical
Poisson regression and the estimated relative excess risks are very
similar to the Bayesian estimates. Comparing the Bayesian models
the DIC for the fully adjusted model is about 730 points lower than
the unadjusted model and substantially lower than each of the
univariate models suggesting that the fully adjusted spatial model
is better supported for the data (Table 3). The fixed effects
estimates in the univariate and fully adjusted models are similar.
From the fully adjusted model the excess mortality associated with
a diagnosis of cancer is 2.27 times higher for men aged 80 and over
at diagnosis compared with men aged 15–59 years at diagnosis
(95% CI 2.02–2.55). There was also significant deprivation effect,
with an RER of 1.43 in the most deprived areas compared with the
most affluent areas (95% CI 1.28–1.58). Men diagnosed later had a
significantly lower excess mortality rate than men diagnosed in the
earlier period (RER¼0.67, 95% CI 0.64–0.71).
Figure 3 shows the unadjusted and fully adjusted RER for each
PCT. As expected many of the PCTs with relative survival rates less
than the NYCRIS rate had RERs higher than 1 and PCTs with
relative survival rates higher than the NYCRIS rates had RERs less
than 1. The unadjusted RER range from 0.76 to 1.66; seven PCTs
have significantly higher RERs compared with the overall NYCRIS
region and seven PCTs have significantly lower RERs. The fully
adjusted RERs range from 0.74 to 1.49, and from the graph we can
see that the fully adjusted model shrinks the RERs towards the
baseline value of 1. The number of PCTs significantly different
from the baseline is reduced to four PCTs with significantly higher
RERs and four PCTs with significantly lower RERs.
Table 4 shows descriptive statistics comparing the adjusted
RERs for the PCTs using a Bayesian and classical approach.
As expected under Bayesian hierarchical spatial analysis, the
PCT-relative excess risk estimates are less dispersed around the
median of 1 than the classical estimates.
In the unadjusted model 70% of the variance between PCTs was
due to spatial effects although the 95% credible interval for this
Log-rank test P-value <0.001 Log-rank test P-value <0.001
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Figure 1 Kaplan–Meier Survival curves by each covariate.
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5-year relative survival by PCT
5AN North East Lincolnshire
5AW Airedale
5CF Bradford City
5CG Bradford South and West
5CH North Bradford
5D4 Carlisle and District
5D5 Eden Valley
5D6 West Cumbria
5D7 Newcastle
5D8 North Tyneside
5D9 Hartlepool
5E1 North Tees
5E2 Selby and York
5E3 East Yorkshire
5E4 Yorkshire Wolds and Coast
5E5 Eastern Hull
5E6 West Hull
5E7 Eastern Wakefield
5E8 Wakefield West
5EF North Lincolnshire
5HH Leeds West
5HJ Leeds North East
5HK East Leeds
5HL South Leeds
5HM Leeds North West
5J6 Calderdale
5J7 North Kirklees
5J8 Durham Dales
5J9 Darlington
5KA Derwentside
5KC Durham & Chester-le-Street
5KD Easington
5KE Sedgefield
5KF Gateshead
5KG South Tyneside
5KH Hambleton and Richmondshire
5KJ Craven, Harrogate & rural district
5KK Scarborough, Whitby & Ryedale
5KL Sunderland Teaching
5KM Middlesbrough
5KN Langbaurgh
5LJ Huddersfield Central
5LK South Huddersfield
TAC Northumberland
Figure 2 Relative survival by PCT.
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swas from 2 to 99%. In each of the univariate models
the percentage of the variance explained by the spatial effects
was similar ranging from 67% for the model adjusted for
period of diagnosis to 72% for the model adjusted for
deprivation. In the fully adjusted model the fraction of the
variation that was spatially structured was 74%, and the width
of the credible interval was narrower, from 14 to 98%. The
percentage of spatially structured variance in the fully adjusted
model was greater than the unadjusted model and the univariate
models suggesting that all three covariates might not be truly
independent.
The maps in Figures 4 and 5 show the unadjusted and fully
adjusted spatially smoothed RERs for each PCT. After adjusting for
the covariates areas of high and low excess mortality were
smoothed towards the mean, the number of PCTs with RER above
1.25 reduced from five to three whereas the number of PCTs with
RER under 0.85 reduced from eight to four. After adjusting for the
covariates area with higher excess risk of deaths were found in
West Cumbria, North Lincolnshire and North East Lincolnshire
whereas the areas with low excess risk of death were found in
Huddersfield Central, South Huddersfield, Darlington and Wake-
field West.
Table 2 Covariate fixed effects of estimates of the relative excess risk of death
Bayesian
Classical
Variable Factor Adjusted for age
Adjusted for
deprivation
Adjusted for
period
Adjusted for age,
deprivation and period
Adjusted for age,
deprivation and period
Fixed effects
Age group 15–59 years 1.0 1.0 1.0
60–69 years 0.99 (0.88, 1.12) 0.99 (0.88, 1.12) 0.99 (0.88, 1.12)
70–79 years 1.29 (1.15, 1.44) 1.28 (1.14, 1.43) 1.27 (1.13, 1.42)
80+ years 2.34 (2.08, 2.64) 2.27 (2.02, 2.55) 2.23 (1.98, 2.51)
Deprivation quintile 1 (most affluent) 1.0 1.0 1.0
2 0.99 (0.88, 1.12) 0.98 (0.88, 1.09) 0.97 (0.87, 1.08)
3 1.23 (1.09, 1.37) 1.21 (1.08, 1.34) 1.21 (1.09, 1.34)
4 1.30 (1.16, 1.46) 1.27 (1.14, 1.41) 1.30 (1.18, 1.44)
5 (most deprived) 1.47 (1.31, 1.64) 1.43 (1.28, 1.58) 1.45 (1.32, 1.60)
Period of diagnosis 1990–1995 1.0 1.0 1.0
1996–2000 0.64 (0.60, 0.68) 0.67 (0.64, 0.71) 0.67 (0.63, 0.71)
Table 3 Variance estimates for the random effects
Variance Unadjusted
Adjusted for age
only
Adjusted for
deprivation only
Adjusted for
period only
Adjusted for age,
deprivation and period
PCT
Unstructured 0.0124 (0.0005, 0.0476) 0.0113 (0.0005, 0.0420) 0.0083 (0.0004, 0.0340) 0.0131 (0.0005, 0.0472) 0.0064 (0.0005, 0.0241)
Structured 0.0286 (0.0010, 0.0510) 0.0245 (0.0013, 0.0452) 0.0218 (0.0010, 0.0395) 0.0269 (0.0015, 0.0502) 0.0177 (0.003, 0.032)
Fraction structured 0.70 (0.02, 0.99) 0.69 (0.04, 0.99) 0.72 (0.03, 0.99) 0.67 (0.04, 0.99) 0.74 (0.14, 0.98)
DIC 19464.8 18996.1 19400.4 19236.2 18738
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Figure 3 Relative excess risks (RER) by PCT.
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sDISCUSSION
Many studies have found that there is regional variation in
prostate cancer survival (Farrow et al, 1996; Dickman et al, 1997;
Post et al, 1998; EUROCARE, 2003; Yu et al, 2004; Berrino et al,
2007), we also found that there are differences in the survival
patterns for PCTs in the NYCRIS region. The estimation of cancer
survival at the PCT level can be problematic due to insufficient
data to obtain robust estimates. In this paper, we have used
Bayesian methods and adjusted for socio-demographic risk factors
to produce survival estimates, in the form of relative excess risks of
death, by PCT for prostate cancer in the NYCRIS region. By
mapping the results we were able to identify the areas where high
excess mortality was evident and where resources may be targeted
to improve outcomes.
The results showed that all of the three included covariates had a
significant association with excess mortality rates, men from more
deprived areas, older age at diagnosis and diagnosed between 1990
and 1994 had higher excess mortality. However, the analysis has
suggested that there may be some other risk factor that we have
not accounted for that influences survival. Both stage of disease at
diagnosis and treatment received will have an impact on patient
survival.
Cancer stage is one of the most important predictors of survival.
In New South Wales, Australia Bayesian models that adjusted for
stage of disease were fitted and significant variation in prostate
cancer survival between regions was found. (Yu et al, 2004) The
cancer registry does not have good quality data on stage for the
Northern part of the NYCRIS region until the late 1990s, therefore,
we are unable to adjust for this in our models and analysis of these
variables over our study period is limited. However, some analysis
on metastases rates across the PCTs based on data from 1998 and
1999 has been carried out (data not shown). The rate of metastases
at presentation by PCT show that the three PCTs with higher
excess risk of death had higher percentages of men presenting with
metastases than the NCYRIS average whereas the four PCTs with
lower excess risks of death had lower percentages of men with
metastases. The differences in the proportions of men presenting
with metastases across the PCTs may help explain some of the
variation in survival that we have observed.
The stage at diagnosis is likely to have changed over time as the
use of PSA testing has become more common in the UK (Brewster
et al, 2000; Evans and Moller, 2003). This increase in PSA testing
has lead to the diagnosis of many cancers earlier and that might
not have been diagnosed in life. By diagnosing many more
tumours earlier survival estimates will increase. We saw in our
study the men diagnosed in the later time period had an excess risk
of death 33% lower than men diagnosed in the earlier half of our
study period.
There is also evidence to suggest that PSA testing is more
common in affluent areas (Melia et al, 2004). Coleman et al (2004)
found that in England and Wales inequality in deprivation
increased over time and part of this increase in inequality could
be because of increased PSA testing in the more affluent groups.
There is likely to be a complex relationship between stage and
deprivation and survival that is not accounted for in our models.
Treatment received for prostate cancer will also have a bearing
on the survival of each individual. Currently in the UK there is no
consensus on the best treatment for prostate cancer (NICE, 2002),
and there are wide variations in the methods of treatment used in
the UK. (Hanna et al, 2002; Payne and Gillatt, 2007) Geographical
differences in treatment have been observed elsewhere (Bauvin
et al, 2003; Krupski et al, 2005) and in our study region there is
some evidence of differences in the treatment of prostate cancer
received by cancer network. (NYCRIS, 2007) Looking at treatment
data across the PCTs for 1998 and 1999 also shows that there is a
wide variation in treatment modality by PCT (data not shown).
This study identified three areas with higher excess risks of
death and four areas with lower risks of death after adjustment for
age at diagnosis, deprivation and period of diagnosis. The age
standardised incidence rates for the PCTs with higher excess risk
were lower than the NYCRIS rate in 1990–1994 (one of these was
statistically significantly lower) and two of the three PCTs had
Table 4 Descriptive statistics comparing adjusted RER for PCTs from
Bayesian spatial and classical methods
Measure Bayesian RER Classical RER
Min 0.74 0.44
25th centile 0.93 0.8
Median 0.99 0.99
75th centile 1.08 1.31
Max 1.49 1.68
Number of PCTs with RER o0.85 4 14
Number of PCTs with RER 41.25 3 12
(8) <0.85
(15) 0.85–1.0
(13) 1.0–1.15
(3) 1.15–1.25    
(5) 1.25 
N
100 km
Figure 4 Map of unadjusted smoothed PCT spatial effects.
(4) < 0.85
(20) 0.85–1.0
(15) 1.0–1.15
(2) 1.15–1.25
(3) 1.25
N
100 km
Figure 5 Map of fully adjusted smoothed PCT spatial effects.
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slower rates than the NYCRIS rate in 1995–1999 (one of these was
statistically significantly lower). All the incidence rates for the four
PCTs with lower excess risks were higher than the NYCRIS rate in
1990–1994 and this was statistically significantly higher in three.
The rates were also higher for these PCTs in 1995–1999 and two of
these were statistically significantly higher. The areas with higher
rates may be diagnosing more cases due to increased use of PSA
testing, therefore increasing survival rates as many of these cases
will have early stage disease. Gavin et al (2004) found that there
was a 100-fold variation in PSA testing rates across general
practises in Northern Ireland, we do not have data to assess the
variation in levels of PSA testing across PCTs but differences in
PSA testing by PCT will influence both incidence rates and survival
rates by PCT.
We found that there was a significant deprivation gradient in the
excess mortality; men from the most deprived areas had an excess
mortality rate that was about 47% higher than that of men from the
least deprived areas, this was attenuated slightly to 43% in the fully
adjusted model. Deprivation was measured at the ward level, we do
not have socio economic information at the individual level so
have to use an area-based measure and should be aware that the
results obtained for each area cannot be extrapolated to the
individuals within that area.
In the fully adjusted model we found that the percentage of
spatially structured variance was greater than the unadjusted models
and the univariate models. This suggests that all three of the
covariates in the model, age, deprivation quintile and period of
diagnosis, might not be truly independent. There was a higher
percentage of younger men diagnosed in 1995–1999 compared to
1990–1994, and there were more younger men diagnosed in affluent
areas compared with the more deprived areas (data not shown).
We compared this spatial fraction after including different
variables in the model to see how much of the geographical
variation between PCTs can be explained by the risk factors. In the
fully adjusted model 74% of the variation in survival is spatially
structured which may indicate that there are some other spatially
structured risk factors that we have not accounted for that may
help explain the variation between the PCTs, for example
differences in treatment or stage at diagnosis by PCT.
Many spatial analysis of incidence and mortality use data at a
smaller geographical level than PCT, maybe ward or output area.
Jarup et al (2002) used Bayesian methods to analyse spatial
variations in prostate cancer incidence by ward in Great Britain
and found there was no marked geographical variation in the risk
of prostate cancer; however, this study used data from 1975 to 1991
before the use of PSA testing was more wide spread in the UK. This
unit of analysis is not suitable for survival analysis as the models
require a certain number of cases/deaths per interval. Also as
treatment may influence survival and many patients will be treated
within the same PCT, the PCT is a more logical geographic unit to
use in survival analysis. However, we did carry a similar analysis
based on ward of residence and found similar results as when we
used the PCT data. There were clusters of wards with the highest
excess risks of death in Cumbria, North Lincolnshire and North
East Lincolnshire.
Bayesian methods are more frequently used to study spatial
variation in cancer survival (Osnes and Aalen, 1999; Henderson
et al, 2002; Yu et al, 2004) The use of Bayesian techniques to model
cancer survival offers many advantages over the traditional
methods. In particular, risk estimates in areas with small
populations or low incidence rates, especially rural areas, are
stabilised and shrunk towards local and global risk estimates. This
improves the reliability and precision of the risk estimates.
Therefore the chance of obtaining excessively high or low
estimates due to the occurrence of sparse data is reduced. Other
advantages of using a Bayesian approach are that it is relatively
easy to fit complex models that allow adjustment for covariates
when assessing geographical variation in survival and we can also
obtain functions of the model parameters such as the relative
contributions of the unstructured and structured spatial effects.
In our models we used an adjacency matrix that was based on
the number of neighbours each PCT had. We used all of the PCTs
in the NYCRIS region and some of these PCTs will border PCTs
that are in a different cancer registry. In our study, these PCTs will
only have recorded the PCTs that are in the NYCRIS region and
this may introduce some bias into the results as these areas have
neighbours missing. The credible interval for the estimates of the
amount of variation that is due to spatially structured effects was
rather wide; ranging from 2 to 99% in the unadjusted model, this
decreased slightly in the fully adjusted model ranging from 14 to
98%. The marginal spatial variance is inversely related to the total
number of areas and in this study we only have 44 areas, the
conditional spatial variance is also inversely proportional to the
number of neighbours each area has and in this study we used
quite large areas and they had relatively few neighbours, therefore
the precision of the variance estimates would be smaller if we had
used more smaller areas with more neighbours (such as wards).
The ability to detect areas where cancer survival is poor is a
useful tool as it indicates where the policy to improve survival
might be best targeted or where further investigation to under-
stand the causes of the poor survival might be best carried out. As
in this study it is important to be able to adjust for some common
confounding variables such as age and deprivation. We feel that
this methodology could be useful to apply to other cancer sites and
geographic areas to gain a better understanding of regional
variation in survival.
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